Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Over A Decade In The Making, MEK Inhibitors Break Through In Melanoma

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

As if moving on from failures of the past, MEK inhibitors are now being positioned as part of the next standard of care in BRAF-mutant melanoma. Glaxo prepares to file trametinib as a monotherapy in 2012, after reporting striking Phase III results, while Novartis/Array’s MEK 162 demonstrates value in area of unmet need.


Related Content

GSK Prices Tafinlar At $7,600/month, Undercutting Roche’s Zelboraf
Tandem Approval Brings GSK’s Tafinlar And Mekinist To A Market Ready To Test Combinations
Glaxo’s Emerging BRAF/MEK Melanoma Combo Threatens Roche’s Zelboraf
Glaxo’s Emerging BRAF/MEK Melanoma Combo Threatens Roche’s Zelboraf
Long And Winding Road To MEK Inhibition
AstraZeneca’s MEK Inhibitor Boosts PFS, But Misses Overall Survival Endpoint In Lung Trial
Oncologists Audition Yervoy And Zelboraf For First-line Roles, With New Combos In Near Sight
GlaxoSmithKline Deals One-Two Punch With BRAF/MEK Pair
Array Biopharma Wins Two Important Deals In Six Months, But Wall Street Shrugs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts